Ribonucleic acid (RNA) transfection of dendritic cells (DCs) was shown to be highly efficient in eliciting CD8
D
endritic cells (DCs) represent the interface between self and non-self antigens and T lymphocytes and play a key role in the regulation of cell-mediated immunity. DCs control and regulate the type of T-cell responses by directing naı¨ve lymphocyte development into defined subclasses of effector cells, for example, Th1, Th2, or regulatory T cells (Treg). 1, 2 It was recently shown that DCs transfected with ribonucleic acid (RNA) coding for tumor-associated antigens (TAAs) or even whole tumor mRNA are able to induce potent antigen and tumor-specific T-cell responses directed against multiple epitopes.
3 -7 This approach does not require the definition of the TAA or human leukocyte antigen (HLA) haplotype of the patients and has the potential of a broad clinical application. Such a polyvalent vaccine may reduce the probability of a clonal tumor escape and elicit cytotoxic T lymphocyte (CTL) responses directed against naturally processed and presented immunodominant tumor antigens. Additional targeting of HLA class II restricted epitopes may further amplify and prolong the induced T-cell responses.
In the present study, we wanted to verify whether electroporation of DCs with RNA coding for a TAA would elicit antigen-specific effector CTL responses and whether these responses could be modulated by cotransfection with a second specific synthetic RNA. Therefore, human monocyte-derived DCs were electroporated with in vitro transcribed RNA coding for the TAA HER-2/neu. Additionally, these cells were cotransfected with synthetic 4-1BBL-RNA as a model for the provision of more effective costimulation to T lymphocytes.
For the induction of a T-cell response, binding of the Tcell receptor (TCR) to a major histocompatibility complex (MHC)-bound peptide (''signal 1'') is not sufficient and additional signaling by costimulatory receptors (''signal 2'') is necessary. These interactions between costimulatory ligands and their receptors are crucial for the activation of T cells, formation of T-cell immunity, and prevention of tolerance. Costimulation enhances the T-cell receptor interactions thereby amplifying the initial activation. Costimulation also promotes cell proliferation and viability and induces effector functions like cytokine secretion or cytotoxicity.
4-1BB is an inducible molecule of the tumor necrosis factor receptor (TNFR) superfamily, that is predominantly expressed on activated CD4 þ and CD8 þ T lymphocytes. Its ligand, 4-1BBL, is expressed on activated antigen-presenting cells (APCs) including DCs and macrophages. The receptor-ligand pair acts as positive regulator on T cells: signaling through 4-1BB by 4-1BBL amplifies the CD8 þ and CD4 þ T lymphocyte-mediated immune response. Additionally, 4-1BB signalling prolongs the survival of CD8
þ cells by prevention of activation-induced apoptosis. [8] [9] [10] [11] Coadministration of HER-2/neu-and 4-1BBL-IVT resulted in an increased specific lysis of target cells by the in vitro induced CTL lines, indicating that 4-1BBL enhances their ability to elicit primary CTL responses. Interestingly, transfection of DCs with 4-1BBL-IVT did not augment their capacity to stimulate allogeneic lymphocyte responses.
In the context of immunotherapies for cancer patients, cotransfection of DCs with tumor-RNA and any second specific synthetic RNA could improve and optimize the in vitro manipulation of DCs for the induction of antigenspecific CTL responses.
Materials and methods

Cell isolation and generation of DCs from adherent peripheral blood mononuclear cells
Generation of DCs from peripheral blood monocytes was performed as described previously. 12, 13 In brief, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll/Paque (Biochrom, Berlin, Germany) density gradient centrifugation of blood obtained from buffy coat preparations of healthy donors from the blood bank of the University of Tu¨bingen. Cells were seeded (1 Â 10 7 cells/3 ml/well) into six-well plates (BD Falcon, Heidelberg, Germany) in RP10 medium (RPMI 1640 with glutamax I, GIBCO s , Invitrogen, Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mmol/l, L-glutamine, 50 mmol/l 2-mercaptoethanol, and antibiotics. After 2 h of incubation at 371C and 5% CO 2 , nonadherent cells were removed, and the adherent blood monocytes were cultured in RP10 medium supplemented with human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF, 100 ng/ml; Leukine s Liquid Sargramostim, Berlex s Laboratories Inc., Richmond) and interleukin 4 (IL-4, R&D, Wiesbaden, Germany; 20 ng/ml). The phenotype of DCs was analyzed by flow cytometry (FACS) after 6 days of culture (data not shown).
Generation of 4-1BBL-, HER-2/neu-, and MUC1-in vitro transcripts
For generation of synthetic 4-1BBL-RNA, a full-length cDNA fragment excised from the plasmid pcDNA3-H4-1BBL (generously provided by TH Watts, T Wen, University of Toronto, Toronto, Canada) was subcloned into the plasmid pSP64 Poly(A) (Promega, Mannheim, Germany) in front of a synthetic poly(A) tail, which allows in vitro transcription under the control of an SP6 promoter. The plasmid was linearized behind the poly(A) tail by restriction enzyme digestion and in vitro transcribed with the SP6 mMESSAGE mMACHINE s kit (Ambion, Huntingdon, UK) according to the protocol provided by the manufacturer. Purification of in vitro transcripts (IVTs) was performed with RNeasy s Mini anion-exchange spin columns (Qiagen, Hilden, Germany) according to the RNA cleanup protocol provided by the manufacturer. For generation of MUC1-IVT, a fulllength polymorphic epithelial mucin (PEM)-cDNA fragment was excised from the plasmid pBS-PEM-tm 14 (generously provided by SJ Gendler, Mayo Clinic College of Medicine, Mayo Clinic Scottsdale, Scottsdale, USA), subcloned into the plasmid pSP64 Poly(A) (Promega) and in vitro transcribed as described above. HER-2/neu-IVT was generated in an analogous manner by linearization and in vitro transcription (using T3 RNA polymerase) of the plasmid pSPJC1-HER-2/neu containing the fulllength HER-2/neu-cDNA inclusive of the poly(A) tail (generously provided by A Ullrich, Max-Planck-Institut fu¨r Biochemie, Mu¨nchen, Germany). Quantity and purity of IVTs were determined by UV spectrophotometry. The IVTs were routinely checked by formaldehyde/agarose gel electrophoresis for size and integrity and stored at À801C in small aliquots.
Electroporation of DCs with in vitro transcribed RNA
Before electroporation on day 6, immature DCs (grown in RP10 medium in the presence of IL-4 and GM-CSF) were washed twice with serum-free XVIVO 20 s medium (BioWhittaker, Apen, Germany) and resuspended to a final concentration of 2 Â 10 7 cells/ml. Subsequently, 200 ml of the cell suspension was mixed with 10 mg of IVT and electroporated in a 4 mm cuvette using an EasyjecT PLUS s unit (EquiBio, Peqlab, Erlangen, Germany). The physical parameters were: voltage of 300 V, capacitance of 150 mF, and resistance of 1540 O. After electroporation, the cells were immediately transferred into RP10 medium and returned to the incubator. 15 Immunostaining Cells were stained using fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated mouse monoclonal antibodies against CD14, CD80, HLA-DR, CD54 (Becton Dickinson, Heidelberg, Germany), CD40, CD86 (PharMingen, Hamburg, Germany), CD1a (Dako Diagnostika, Hamburg, Germany), CD83 (Immunotech, Marseille, France), and mouse IgG isotype control (Becton Dickinson). Cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). To calculate the percentage of positive cells, a proportion of 1% falsepositive events was accepted in the negative control samples throughout.
Induction of antigen-specific CTL responses
The induction of HER-2/neu-specific CTLs was performed as described previously. 12, 16, 17 The HLA-A2-binding peptides derived from HER-2/neu, E75 (amino acids 369-377: KIFGSLAFL), and GP2 (amino acids 654-662: IISAVVGIL) 16 and the control peptide HIV (pol (human immunodeficiency virus), HIV-1 reverse transcriptase peptide (amino acids 476-484: ILK-EPVHGV) were synthesized using standard F-moc chemistry on a peptide synthesizer (432A, Applied Biosystems, Weiterstadt, Germany) and analyzed by reversed-phase high-performance liquid chromatography and mass spectrometry. For induction of HER-2/neuspecific CTLs, DCs were electroporated with HER-2/neu-IVT as described above, washed, and incubated with 3 Â 10 6 PBMCs. After 7 days of culture, cells were restimulated with autologous electroporated DCs, and 2 ng/ml IL-2 (R&D Systems) were added on days 1, 3, and 5. The cytolytic activity of induced CTLs was analyzed on day 5 after the last restimulation in a standard 51 Crrelease assay.
51
Cr-release assay (CTL assay)
The standard 51 Cr-release assay was performed as described previously. 12, 16, 17 Target cells were electroporated with HER-2/neu-IVT or pulsed with 50 mg/ml peptide for 2 hours and labeled with [
51 Cr]-sodium chromate for 1 hour at 371C. Then, 1 Â 10 4 cells were transferred to a well of a round-bottom 96-well plate. Varying numbers of CTLs were added to a final volume of 200 ml and incubated for 4 hours at 371C. At the end of the assay, supernatants (50 ml/well) were harvested and counted in a b-plate counter. The percentage of specific lysis was calculated as: 100(experimental releaseÀsponta-neous release/maximal releaseÀspontaneous release). Spontaneous and maximal releases were determined in the presence of either medium or 2% Triton X-100, respectively. All experiments were performed at least three times.
Proliferation assay (mixed lymphocyte reaction, MLR)
The DCs used as stimulators were washed with phosphate-buffered saline (PBS, GIBCO s ) and diluted to obtain a concentration of 1 Â 10 5 cells in 100 ml RP10 medium in quadruple. The diluted cells were irradiated with 30 Gy and seeded in flat-bottom 96-well plates. In all, 1 Â 10 5 allogeneic PBMCs were added in 100 ml RP10 medium. After an incubation period at 371C/5% CO 2 of 5 days, the lymphocytes were pulsed with 3 H-thymidine (0.5 mCi/well, Amersham, Buckingham, UK) for 16 hours and harvested for analysis. Thymidine incorporation was measured on a 1205 Betaplate s liquid scintillation counter (Perkin Elmer Wallac, Freiburg, Germany).
Results
Electroporation of DCs with 4-1BBL-IVT upregulates the expression of CD40 and CD80
To determine whether the electroporation of immature monocyte-derived DCs with 4-1BBL-IVT affects their phenotype, FACS analysis for characteristic monocyte and DC markers was performed 24 hours post-transfection. As a control, immature DCs transfected with MUC1-IVT were used. As shown in the overlay histograms (Fig 1) , DCs electroporated with MUC1-IVT or transfected with 4-1BBL-IVT both show a typical phenotype of immature DCs: absence of CD14, expression of CD1a
and CD40
þ . However, the FACS analysis revealed a higher expression of the costimulatory molecules CD80 and CD40 of DCs transfected with 4-1BBLRNA as compared to the control, thus indicating that 4-1BBL can mediate activation of DCs.
DCs electroporated with HER-2/neu-IVT present HER-2/ neu-derived epitopes
In the next set of experiments, we analyzed the presentation of HER-2/neu-derived epitopes after electroporation of DCs with in vitro transcribed HER-2/neu-RNA. To accomplish this, we first induced HER-2/neu-specific CTLs using DCs pulsed with the HLA-A2 binding HER-2/neu-derived peptides E75 and GP2. The cytolytic activity of generated CTLs was determined after two weekly restimulations in a standard 51 Cr-release assay. As target cells, we utilized the tumor cell lines A498 (HER-2/ neu
, K-562, peptide loaded DCs (E75, GP2 and HIV peptide), and DCs electroporated with HER-2/neu-IVT. As shown in Figure 2 , the CTL lines showed peptide-specific and HLA-A2- Cotransfection of dendritic cells with 4-1BBL-RNA F Grünebach et al restricted killing of DCs pulsed with the cognate peptides E75 and GP2 used for CTL induction and tumor cell lines constitutively expressing HER-2/neu. DCs electroporated with pure HER-2/neu-IVT were efficiently lysed confirming the expression of HLA-A2-restricted HER-2/neuassociated antigens upon electroporation with in vitro transcribed RNA. DCs pulsed with the irrelevant HIV peptide as well as HLA-A2-negative cell lines were spared. There was also no lysis of K-562 cells, thus excluding a natural killer (NK) cell-mediated recognition.
Induction of HER-2/neu-specific CTLs by DCs electroporated with HER-2/neu-IVT can be increased upon cotransfection with 4-1BBL-IVT
We next analyzed the ability of DCs electroporated with HER-2/neu-IVT to elicit HER-2/neu-specific CTL responses in vitro and examined whether cotransfection of DCs with 4-1BBL-IVT can increase the induction of antigen-specific CTLs. For the induction of a primary CTL response, monocyte-derived DCs were electroporated with HER-2/neu-IVT and used as APCs. As shown in Figure 3a after two weekly restimulations with HER-2/ neu-transfected DCs, the CTL lines showed antigen specific killing of tumor cell lines expressing constitutively HER-2/neu as well as the autologous DCs electroporated with pure HER-2/neu-IVT. These experiments demonstrate that DCs loaded with RNA can very efficiently induce antigen-specific CTLs. In a parallel experiment, DCs were electroporated with HER-2/neu-IVT and an equal amount of 4-1BBL-IVT and used as APCs. Standard 51 Cr-release assays again showed peptidespecific and HLA-A2-restricted cytotoxic activity of the generated CTLs against autologous DCs transfected with HER-2/neu-RNA and against the HLA-matched allogeneic HER-2/neu þ /HLA-A2 þ renal cell carcinoma cell line A498, whereas DCs loaded with the irrelevant HIV peptide as well as HER-2/neu À /HLA-A2 þ CROFT cells (Fig 3b) . However, coadministration of HER-2/ neu-RNA with 4-1BBL-RNA resulted in an increased specific lysis of target cells by the in vitro induced CTL lines (50 vs 90% specific lysis at an effector-to-target ratio of 30:1 for the DCs electroporated with HER-2/neu-IVT; Figure 3a , b), thus indicating that cotransfection of DCs with 4-1BBL enhances their ability to elicit primary CTL responses.
Transfection with 4-1BBL-IVT does not augment the capacity of DCs to stimulate allogeneic lymphocyte responses
To analyze the effect of 4-1BBL transfection on the allogeneic stimulation of the T-cell proliferation, we performed mixed lymphocyte reactions. DCs transfected with 4-1BBL-IVT, irrelevant MUC1-IVT, or left untreated were cocultivated with allogeneic PBMCs for 5 days and pulsed with 3 H-thymidine. Interestingly, we found that the electroporated DCs showed higher stimulatory capacity as compared to the untreated (Fig 4) . However, no significant differences could be observed between DCs electroporated with MUC1-or 4-1BBL-IVT indicating that 4-1BBL does not contribute to the stimulation of unspecific allogeneic T-cell proliferation.
Discussion
DCs are the most powerful professional APCs with the ability to initiate and maintain primary immune responses. Recently, several procedures to generate large numbers of DCs from circulating precursors, including peripheral blood monocytes and CD34 þ stem cells, have been developed for their clinical use to treat patients with infections and malignant diseases. Hence, numerous attempts to optimize delivery of tumor antigens to DCs, as well as routes and schedules of administration to cancer patients, are currently analyzed in clinical trials. [18] [19] [20] [21] [22] Recently, it has been demonstrated that transfection of DCs with specific or whole-cell RNA is more effective than transfection with DNA-vector constructs. 15 A multitude of studies demonstrated the power of this approach to induce antigen-specific CTLs in vitro and in vivo.
The goal of recent studies is to manipulate DCs using genetically engineered RNA. Thus, for example, Su et al. 23 sought to determine whether human DCs transfected with RNA encoding a chimeric protein, consisting of the lysosome-associated membrane protein (LAMP-1) and human telomerase reverse transcriptase (hTERT), are capable of stimulating concomitant hTERT-specific CD8 þ and CD4 þ T-cell responses in vitro. In another study, Nair et al 24 obtained synergistic effects of tumor-immunotherapy and antiangiogenic therapy on the platform of RNA transfected DCs. In line with these attempts, the purpose of the present study was to proove the principle of RNA cotransfection to further modulate the CTL responses elicited by the transfected DCs.
As a model for a ''second signal'', we chose 4-1BBL, a type II transmembrane protein and a member of the tumor necrosis factor superfamily that is expressed by activated APCs including B cells and macrophages. Interaction of 4-1BBL with 4-1BB is reported to deliver a costimulatory signal important in the T cell-APC interaction. 4-1BBL knockout mice accumulate significant lower numbers of antigen-specific CD8 þ cells and induce less memory T cells. 10, [25] [26] [27] However, knocking out the 4-1BBL gene does not impair the initial proliferation of CD8
þ cells in primary immune responses but suppresses their accumulation by inducing apoptosis in cells that have already divided several times. 28 Antibodies directed against 4-1BB or 4-1BBL have similar effects: agonistic antibodies augment the immune response by cytotoxic or helper T lymphocytes in vivo. The initial proliferation of cells is not inhibited by anti 4-1BBL-antibodies. This suggests that signaling by 4-1BBL ligation becomes operative after initial T-cell activation by CD28. In fact, in the presence of high amounts of anti-CD3 antibodies, 4-1BBL signaling is independent from signals mediated by CD28 since CD28 þ / þ as well as 
CD28
À/À CD4 þ , and CD8 þ T cells are susceptible for 4-1BBL-mediated stimulation. 29, 30 Recently, Wiethe et al examined whether immunization with DCs expressing a model TAA delivered by an adenoviral vector would elicit TAA-directed effector and memory CTL responses in mice, and whether these responses would be enhanced by coprovision to the DCs of exogenous 4-1BBL. The authors found that 4-1BBL expression led to the upregulation of CD80 and CD86 in the DCs and the mice exhibited elevated tumor-specific effector and memory CTL responses. 31 In accordance with these data, our study using human monocyte-derived DCs shows that DCs electroporated with 4-1BBL-IVT show a typical phenotype but upregulated the costimulatory molecule CD80. In contrast to Wiethe et al's data, we did not observe a significant upregulation of CD86. However, we formed an additional increase of CD40 expression on the DCs. The primary activation of naive T cells requires two independent signals: signal 1, the interaction between MHC-peptide complex and TCR/CD4 or TCR/CD8 and signal 2, interaction between B7.1/B7.2 (CD80/CD86) and CD28 and other costimulatory molecules. Although in combination with strong TCR triggering, 4-1BB signaling can function independently of CD28, it was reported that introduction of 4-1BBL into cells amplifies its immunogenicity in synergy with the CD28 costimulatory pathway. [32] [33] [34] In mice, in the absence of strong TCR signaling, the positive effect of 4-1BB triggering on the induction of CTLs is dependent on the presence of an intact CD28 costimulatory signal. 34 Furthermore, CD28 costimulation of antigen-stimulated T cells is an important signal for 4-1BB upregulation on naive T cells, thereby making these cells susceptible for 4-1BB triggering. Taking these facts into account, our own data suggest the following mechanism: provision of 4-1BBL in the form of IVT to DCs leads to an upregulation of CD80 on these cells thereby, amplifying the interaction with CD28 on T cells. The amplified CD28 costimulation provides a signal for the 4-1BB upregulation on naive T cells, which again results in increased 4-1BB-4-1BBL costimulation.
CD40 functions in the adaptive immune response as a trigger for the expression of costimulatory molecules for efficient T-cell activation. CD40 ligation of DCs also has the capacity to induce high levels of the cytokine IL-12, which polarizes CD4 þ T cells toward a T helper 1 (Th1) type, enhances proliferation of CD8 þ T cells, and activates NK cells. CD40 may also play an important role in the decision between tolerance and immunity and the generation of regulatory CD4 þ T cells that are thought to maintain peripheral self-tolerance in vivo.
We found, that 4-1BBL-IVT transfection into DCs upregulates CD40. It is well known that signaling by CD40 acts as a DC maturation stimulus in vitro, increasing the expression of CD80, CD86, 4-1BBL, CD27L, and OX40L, enhancing antigen presentation and inducing IL-12 production. 8, [35] [36] [37] Hence, the increased expression of CD40 could be the initial trigger of a positive feedback loop via CD80-CD28 and 4-1BB-4-1BBL that leads to an increased induction of antigen-specific CTLs. 51 Cr-release assays in our study revealed that cotransfection of HER-2/neu-IVT with 4-1BBL-IVT nearly doubles the antigen-specific lysis of target cells, thus indicating that cotransfection of DCs with 4-1BBL enhances their ability to elicit primary CTL responses. These findings are supported by several other studies that found, that 4-1BB-4-1BBL interactions regulate the outcome of MHC class I-restricted priming, provide survival signals to primed cells and increase the number of effector CD8 þ cells. 38, 39 Finally, we could demonstrate that the effects mediated by 4-1BBL-RNA transfection are not involved in the unspecific stimulation of allogeneic T-cell proliferation. Accordingly, DeBenedette et al 25 showed in mice that the absence of CD28 or 4-1BBL alone had no effect in skin allograft rejection whereas a lack of both 4-1BBL and CD28 resulted in a delay in allograft rejection. Thus, the authors postulated an implication of 4-1BBL in allogeneic T-cell responses only in the absence of CD28 costimulation. Additionally, we found that the electroporated DCs showed somewhat higher stimulatory capacity as compared to the untreated cells. This suggests that electroporation pulses alone influence the stimulatory capacity of the cells. In contrast, previous reports described that electroporation of immature DCs has no effect on the DC phenotype. 15, 40 In summary, our study revealed that 4-1BBL can signal activation of DCs that leads to upregulation of costimulatory molecules. Furthermore cotransfection with 4-1BBL-IVT increases the specific effector functions of induced CTLs while not affecting unspecific proliferation thus demonstrating that this molecule is important during the antigen-specific priming and not unspecific T-cell stimulation.
Preclinical in vitro studies for the induction of antigenspecific CTLs by DCs transfected either with defined TAA or even with whole tumor RNA demonstrated the power and feasibility of this approach. The principle of RNA cotransfection of DCs with a second specific synthetic RNA, for example, coding for a costimulatory molecule, established in the present study could improve and optimize the in vitro manipulation of DCs for the induction of antigen-specific CTL responses for immunotherapies for cancer patients.
